Format
Sort by

Send to:

Choose Destination

Search results

Items: 4

1.

Blisibimod for treatment of systemic lupus erythematosus: with trials you become wiser.

Scheinberg MA, Hislop CM, Martin RS.

Expert Opin Biol Ther. 2016 May;16(5):723-33. doi: 10.1517/14712598.2016.1169270.

PMID:
27051973
2.

Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.

Nagamani SC, Diaz GA, Rhead W, Berry SA, Le Mons C, Lichter-Konecki U, Bartley J, Feigenbaum A, Schulze A, Longo N, Berquist W, Gallagher R, Bartholomew D, Harding CO, Korson MS, McCandless SE, Smith W, Vockley J, Kronn D, Zori R, Cederbaum S, Merritt JL 2nd, Wong D, Coakley DF, Scharschmidt BF, Dickinson K, Marino M, Lee BH, Mokhtarani M.

Mol Genet Metab. 2015 Sep-Oct;116(1-2):29-34. doi: 10.1016/j.ymgme.2015.08.002. Epub 2015 Aug 5.

PMID:
26296711
3.

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.

Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C, Martin RS, Scheinberg MA; PEARL-SC Study.

Ann Rheum Dis. 2015 Sep;74(9):1667-75. doi: 10.1136/annrheumdis-2013-205144. Epub 2014 Apr 19.

PMID:
24748629
4.

Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.

Fraser H, Hislop C, Christie RM, Rick HL, Reidy CA, Chouinard ML, Eacho PI, Gould KE, Trias J.

J Cardiovasc Pharmacol. 2009 Jan;53(1):60-5. doi: 10.1097/FJC.0b013e318195bfbc.

PMID:
19129734
Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk